Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Division of Internal Medicine, Subdivision of Rheumatology, Maastricht University Hospital, P Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands. Annals of the rheumatic diseases
(Impact Factor: 10.38).
06/2010; 69(6):1010-4. DOI: 10.1136/ard.2009.127332
Glucocorticoids (GCs) rapidly reduce disease activity in early and advanced rheumatoid arthritis (RA). This systematic review on behalf of the task force on recommendations for the management of RA addresses the efficacy of GCs in RA. A literature search was performed in Medline, Embase, the Cochrane database, and the ACR/EULAR abstracts 2007 and 2008 on a set of questions relating to the use of GCs in RA. Eleven publications (including three Cochrane reviews comprising 33 trials) that met the criteria for detailed assessment were found. Robust evidence that GCs are effective as bridging therapy was obtained. The addition of GCs, to either standard synthetic disease-modifying antirheumatic drug (DMARD) monotherapy or combinations of synthetic DMARDs, yields clinical benefits and inhibition of radiographic progression that may extend over many years. In early RA, the addition of low-dose GCs (<7.5 mg/day) to DMARDs leads to a reduction in radiographic progression; in longstanding RA, GCs (up to 15 mg/day) improve disease activity. There is some evidence that appropriate timing of GC administration may result in less morning stiffness. Only indirect information was found on the best tapering strategy, supporting the general view that GCs should be tapered slowly in order to avoid clinical relapses. GCs are effective in relieving signs and symptoms and inhibiting radiographic progression, either as monotherapy or in combination with synthetic DMARD monotherapy or combination therapy.
Available from: Ching-Mao Chang
- "bone erosion and progressive disability. Even more, it also hampers somatic systems, resulting in cardiovascular disease, interstitial lung disease, osteoporosis (Gorter et al., 2010; Saag et al., 2008; Sesin and Bingham, 2005; Smolen et al., 2010) and mortality (Gonzalez et al., 2007; Mok et al., 2011). Non-steroid anti-inflammation drugs (NSAIDs) and Disease-modifying antirheumatic drugs (DMARDs) are conventionally used to suppress inflammation and modulate immunity (O'Dell, 2004; Saag et al., 2008; Smolen et al., 2010). "
[Show abstract] [Hide abstract]
ABSTRACT: Ethnopharmacological relevance:
Large-scale study of traditional Chinese medicine (TCM) usage among patients with rheumatoid arthritis (RA) is lacking. The aim of this study is to evaluate the TCM usage among RA patients in Taiwan.
Materials and methods:
We examined the "registry for catastrophic illness patient dataset" of the National Health Insurance Research Database (NHIRD; n=23 million people) in Taiwan. Patients (n=25,263) newly diagnosed as RA in 2001-2009 were included and then followed-up until the end of 2011. Based on the medical utilization, they were further categorized into TCM users (n=6,891; 27.3%) and non-TCM users (n=18,372; 72.7%). The demographic data and core prescription patterns of the TCM users were analyzed.
Compared to non-TCM user, TCM users were younger (mean age: 49.6 versus 54.0 years), had a higher female/male ratio (82.7%/17.3% versus 74.1%/25.9%), resided in more urbanized area. Herbal remedies were the most commonly used therapeutic approach (76.4%), followed by combining acupuncture (21.1%). The frequency of outpatient visits in TCM users was higher across all disease categories except circulatory system. The most commonly prescribed formula and herb was Shang-Jong-Shiah-Tong-Yong-Tong-Feng-Wan and Rhizoma Corydalis, respectively. The analysis of core pattern revealed that Dang-Gui-Nian-Tong-Tang, Shu-Jing-Huo-Xie-Tang, Gui-Zhi-Shao-Yao-Zhi-Mu-Tang, Myrrha and Olibanum, were among the most frequently used combinations. RA patients who had anxiety and depression, allergic rhinitis, osteoporosis, menstrual disorder, and menopausal syndrome were prone to have more TCM visits compared to non-TCM users.
Our population-based study revealed the high prevalence and specific usage patterns of TCM in the RA patients in Taiwan. The information could be used for further pharmacological investigation and clinical trials.
Journal of ethnopharmacology 10/2015; DOI:10.1016/j.jep.2015.10.024 · 3.00 Impact Factor
Available from: Lotta Ljung
- "Thus, the treatment of LORA patients with corticosteroids did not reduce radiological progression, despite the positive effects of these drugs on inflammatory activity. Treatment with low doses of prednisolone as a monotherapy, or in combination with DMARDs, has previously been reported to have positive effects with respect to the remission rate and inhibition of radiographic progression [46-48]. However, contrasting results were reported by Paulus et al., who found that monotherapy with low-dose corticosteroids did not prevent radiological progression . "
[Show abstract] [Hide abstract]
ABSTRACT: Disease activity, severity and co-morbidity contribute to increased mortality in patients with rheumatoid arthritis (RA). We evaluated the impact of age at disease onset on prognostic risk factors and treatment in early disease.
In this study, 950 RA patients were followed regularly from inclusion (<12 months from symptom onset) for disease activity (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tender/swollen joints, visual analogue scale (VAS) pain/global, disease activity score (DAS28)) and function (health assessment questionnaire (HAQ)). Disease severity, measured by radiographs of hands/feet (erosions, Larsen score), extra-articular disease, nodules and co-morbidities and treatment (disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, biologics, nonsteroidal anti-inflammatory drugs (NSAIDs)) were recorded at inclusion and after 5 years. Autoantibodies (rheumatoid factor (RF), anti-nuclear antibodies (ANA), antibodies against cyclic citrullinated peptides (ACPA)) and genetic markers (human leukocyte antibody (HLA)-shared epitope, protein tyrosine phosphatase nonreceptor type 22 (PTPN22)) were analyzed at inclusion. Data were stratified as young (YORA) and late (LORA) onset RA, defined as being below/above median age (58 years) at onset.
LORA was associated with lower frequency of ACPA (P <0.05) and carriage of PTPN22-T variant (P <0.01), but with greater disease activity at inclusion measured as ESR (P < 0.001), CRP (P <0.01) and accumulated disease activity (area under the curve for DAS28) at 6 (P <0.01), 12 (P <0.01) and 24 months (P <0.05), and a higher HAQ score (P <0.01) compared with YORA. At baseline and 24 months, LORA was more often associated with erosions (P <0.01 for both) and a higher Larsen score (P <0.001 for both). LORA was more often treated with corticosteroids (P <0.01), less often with methotrexate (P <0.001) and biologics (P <0.001). YORA was more often associated with early DMARD treatment (P <0.001). Multiple regression analyses supported our findings regarding impact of age on chosen treatment.
YORA patients were more frequently ACPA-positive. LORA was more often associated with erosions, higher Larsen scores, disease activity and HAQ at baseline. Nevertheless, YORA was treated earlier with DMARDs, whilst LORA was more often treated with corticosteroids and with less DMARDs in early disease. This could have implications for development of co-morbidities.
Arthritis research & therapy 04/2014; 16(2):R94. DOI:10.1186/ar4540 · 3.75 Impact Factor
[Show abstract] [Hide abstract]
Ausgangspunkt der neuen S1-Leitlinie waren die 2010 erschienenen EULAR Recommendations zum Management der rheumatoiden Arthritis (RA), die nach umfangreichen systematischen Literaturrecherchen (SLR) evidenzbasiert erstellt worden sind. Die SLR wurde für die deutschen Empfehlungen aktualisiert und wird in ihrer Methodik vorgestellt.
Die SLR wurde für den Zeitraum von Januar 2009 bis Ende August 2011 durchgeführt. Es wurden alle kontrollierten Studien eingeschlossen, die die krankheitsmodifizierende Therapie der RA hinsichtlich ihrer Wirksamkeit auf Klinik, Funktion und Struktur untersucht haben.
Von 6869 gesichteten Arbeiten wurden 138 Artikel und 56 Abstracts für die Erstellung der Leitlinie berücksichtigt. Auf einem Konsensustreffen wurden die Ergebnisse der SLR vorgestellt. Auf dieser Grundlage formulierte das Expertengremium modifizierte Empfehlungen und verabschiedete diese mittels Konsensus.
Mithilfe der aktualisierten SLR konnten wesentliche neue Daten im Entscheidungsprozess für die neue S1-Leitlinie zur medikamentösen Therapie der RA berücksichtigt werden.
Zeitschrift für Rheumatologie 09/2012; 71(7). DOI:10.1007/s00393-012-1048-y · 0.61 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.